Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir

Abstract

Key Clinical MessageThere is currently minimal clinical experience regarding retreatment options for patients failing direct‐acting antiviral combination regimens. Here, we report the outcomes of a HCV genotype 1b‐infected patient with virologic failure following treatment with daclatasvir and asunaprevir, who was successfully retreated with sofosbuvir plus simeprevir.

Pooled Analysis of HCV Genotype 1 Resistance-Associated Substitutions in NS5A, NS3 and NS5B pre- and Post-Treatment with 12 Weeks of Daclatasvir, Asunaprevir and Beclabuvir

“…Low fitness and subsequent wild-type replacement of both NS3 and NS5B RAS suggests that many patients with virological failure and resistance to NS3 protease or NS5B thumb-1 inhibitors could potentially be retreated with similar agents after 6-12 months off therapy. However, although a successful case of GT-1b retreatment with an NS3 protease inhibitor (simeprevir) and the nucleotide NS5B inhibitor sofosbuvir has been reported in a patient who had relapsed 6 months previously with NS3-D168V following DCV+ASV treatment [40], no baseline sequence data were available and this hypothesis requires empirical testing.…”

Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure

“…In a case report recorded by Safadi et al ., retreatment with SOF in combination with SIM resulted in a rapid viral decline at week 2 that resulted in undetectable HCV RNA at retreatment week 4. The patient achieved an SVR at both post-retreatment weeks 12 and 24 [ 10 ].…”